Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
1 Articles
1 Articles
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Includes $30M at Close to Refinance Existing Debt Facility LANGHORNE, Pa.–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara’s balance sheet following the submission of the…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage